Taken together, these results indicate that sPLA2-IIF promotes epidermal hyperplasic diseases including psoriasis and skin cancer and that P-LPE, a primary sPLA2-IIF product, represents a biomarker and bioactive lipid that reflects the expression and function of sPLA2-IIF. This evidence concerns the gene PLA2G2A and psoriasis.